Moderna’s pioneering COVID shot turned the company into a nearly $200 billion biotech giant and a public health hero. Its ...

Now, what about the second booster, which, for people who received Pfizer and Moderna, would be their fourth shot? Who's eligible? Well, right now, you're eligible for a second COVID-19 booster if ...

MRNA intends to use the funds to support the development of its mRNA-based bird flu shot and expand clinical studies for ...

Demand for its COVID vaccine has been waning since the pandemic, while adoption of its RSV shot - its second approved product- has been slower than expected, forcing Moderna to cut costs.

Moderna (MRNA) stock gained in the premarket after the company received a tender to supply its COVID-19 vaccine in the EU, ...

Moderna has been scaling back its financial targets as demand for its Covid shot has waned post-pandemic and its second product, an RSV shot, has gained little traction so far. The company is also ...

The shot played an instrumental ... The allure of Moderna as an investment lies in its proven leadership in mRNA technology. Nevertheless, securing a second blockbuster drug will be crucial ...

Demand for its COVID vaccine has been waning after the pandemic, while adoption of its RSV shot - its second approved product- has been slower than expected, forcing Moderna to cut costs.